## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.8% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($215.50)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer**
- Source: PR Newswire | 20251205T082649 | Bullish | Relevance: 99%
-  An AbbVie-sponsored symposium at ESMO Asia 2025 addressed the critical need for new strategies to define and treat platinum resistance in advanced ovarian cancer. Experts highlighted that platinum-resistant advanced ovarian cancer has a poor prognosis and current treatment options are limited and often accompanied by significant side effects, affecting patients' quality of life. The discussion emphasized exploring novel approaches, including Antibody Drug Conjugates (ADCs), to improve efficacy, tolerability, and patient outcomes in this challenging disease.

**2. Amundi Purchases 2,435,372 Shares of AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251205T110810 | Bullish | Relevance: 98%
-  Amundi significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 36.6%, purchasing an additional 2,435,372 shares. This acquisition brings Amundi's total holding to 9,093,696 shares, valued at approximately $1.73 billion, making AbbVie its 22nd largest holding. AbbVie recently reported strong Q3 earnings, beating analyst estimates, and announced an increased quarterly dividend of $1.73 per share.

**3. M Holdings Securities Inc. Increases Holdings in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251205T190730 | Bullish | Relevance: 98%
-  M Holdings Securities Inc. significantly increased its stake in AbbVie Inc. (NYSE:ABBV) by 68.6% in the second quarter, bringing its total holdings to 16,979 shares valued at $3.12 million. This move comes as AbbVie reported strong Q3 results, beating earnings estimates and raising its quarterly dividend. The company also received positive sentiment from Wall Street analysts, with an average "Moderate Buy" rating.

**4. AbbVie looks to expand use cases for migraine drug after promising study**
- Source: Crain's Chicago Business | 20251203T051600 | Bullish | Relevance: 98%
- AbbVie is seeking European approval to expand the use of its migraine drug atogepant for acute treatment after a phase three study showed effectiveness in relieving pain two hours after a migraine attack. The drug is currently approved for migraine prevention, and AbbVie aims to broaden treatment options for patients. In the first three months of 2025, the drug, marketed as Qulipta in the U.S. and Aquipta in the EU, reported U.S. sales of $661 million and international sales of $87 million.

**5. Portfolio Design Labs LLC Has $571,000 Stake in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251203T020855 | Somewhat-Bullish | Relevance: 98%
-  Portfolio Design Labs LLC reduced its stake in AbbVie Inc. by 60.6% in Q2, ending with 3,077 shares valued at $571,000. AbbVie surpassed Q3 earnings and revenue estimates and increased its quarterly dividend to $1.73 per share. Analysts have a "Moderate Buy" consensus rating on AbbVie with an average price target of $241.85.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($0.06M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.42 indicates undervaluation relative to growth. Forward P/E 15.9x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $394.1B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.42 |
| Forward P/E | 15.9 |
| Current P/E | 21.2 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from -4.6% to -2.8% (+1.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.8pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.52), momentum weakening. RSI neutral at 48.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.80% (CS: 24) | Weak |
| RSI_14 | 47.8 | Neutral |
| MACD Histogram | -0.52 | Bearish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 0.991x | Below |
| vs SMA200 | 1.105x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $226.08
- **Stop Loss:** $215.50 (4.7% risk)
- **Target:** $236.66 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 47
- **Position Value:** $10,625.76
- **Portfolio %:** 10.63%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*